title: Response to: 'Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required' by Moots et al.
authors.affiliation: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
authors.forename: Paul
authors.initials: P
authors.lastname: Emery
authors.affiliation: Institute of Rheumatology, Prague, Czech Republic.
authors.forename: Jiří
authors.initials: J
authors.lastname: Vencovský
authors.affiliation: Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.
authors.forename: Jeehoon
authors.initials: J
authors.lastname: Ghil
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001685:Biological Factors / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D006801:Humans
chemical_list: D018501:Antirheumatic Agents; D001685:Biological Factors; D001688:Biological Products
keywords: Autoantibodies; DMARDs (biologic); Rheumatoid Arthritis